KOYUN, D. Et Al. 2024. Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma. Indian Journal of Hematology and Blood Transfusion .

KOYUN, D., Şahin, U., Gökmen, A., & ÖZCAN, M., (2024). Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma. Indian Journal of Hematology and Blood Transfusion .

KOYUN, DERYA Et Al. "Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma," Indian Journal of Hematology and Blood Transfusion , 2024

KOYUN, DERYA Et Al. "Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma." Indian Journal of Hematology and Blood Transfusion , 2024

KOYUN, D. Et Al. (2024) . "Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma." Indian Journal of Hematology and Blood Transfusion .

@article{article, author={DERYA KOYUN Et Al. }, title={Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma}, journal={Indian Journal of Hematology and Blood Transfusion}, year=2024}